Freespira is the only FDA-cleared treatment device proven to reduce or eliminate panic attacks and post-traumatic stress disorder (PTSD) symptoms. Unlike medication or talk therapy, in 28 days Freespira addresses the underlying breathing irregularities for individuals suffering from these debilitating anxiety conditions. Freespira’s at-home treatment is available to Veterans with VA benefits.
Typical traumatic stress or panic disorder symptoms may include:
SHORTNESS OF BREATH
Proven to help Veterans 3
To assess Freespira, researchers from the VA Palo Alto Health Care System recruited local community members diagnosed with trauma. After participating in the 28-day Freespira treatment, a majority of patients enrolled in the study reported significant clinical improvement, with many achieving remission.
Veterans Report Sleep Problems, Panic Attacks and Anxiety as Most Troubling Symptoms.4
The symptoms survey respondents say they most want to resolve:
Freespira is easy to use, with 77% average adherence to the twice-a-day treatment over the 28-day protocol among participants in a study by VA researchers. (Ostacher et al., 2021)
Freespira is shipped directly to the patient's home after it has been authorized by the VA.
Freespira is the only FDA-cleared, medication-free digital therapeutic treatment proven to reduce or eliminate PTSD symptoms and panic attacks.
Freespira coaches provide one-on-one training and tech support on how to use the system. (Coaches do not provide clinical care.*)
Relief for veterans at the ready
Freespira can be used with talk therapy and medication.
After authorization, veterans will receive the Freespira system, which includes a sensor, a small breath-sampling tube (cannula), and a tablet with an app.
Dedicated coaches provide virtual one-on-one training and tech support as needed during the 28-day treatment.*
The treatment corrects irregular breathing patterns—underlying physiologic factors with PTSD and repeated anxiety attacks—and trains the body to reduce or eliminate them.
Freespira is listed on the Federal Supply Schedule 65lla – 36F79720D0158, through our SDVOSB partner, Franklin Young International, Inc.
Frequently Asked Questions
No, they provide training, tech support, encouragement and help the Veteran successfully complete treatment. This support was a component of the studies that formed the basis of the FDA clearances.
No, the equipment is only used for 17 minutes, twice daily (unlike remote monitoring devices, which are continuous). In addition, physiologic data (carbon dioxide levels and respiration rates) are uploaded after the session is complete so the user cannot be monitored in real time.
Freespira is a treatment that utilizes a medical device to enable the treatment protocol.
Neither. The equipment is provided for use during the treatment period along with training, coaching and reporting. There is a one-time fee for all necessary elements of the treatment.
The referring provider maintains clinical oversight. If requested, the provider can access a secure server with session records to see progress during the 28-day treatment. In addition, if requested, the referring provider will receive a post-treatment summary report via a secure email after treatment is complete.
Freespira received FDA clearance based on a 28-day protocol with weekly changes to targeted breathing rates.
Thanks for your interest in Freespira!Tell us a few details to proceed.
*Freespira coaches are licensed clinicians, but they do not provide clinical diagnoses, clinical assessments, or clinical guidance to veterans. They are available to answer questions and help veterans undergoing Freespira treatment use the system and promote protocol adherence.
1 See Konnopka, et al., https://pubmed.ncbi.nlm.nih.gov/31646432/
2 See National Academies, https://pubmed.ncbi.nlm.nih.gov/25077185/
3 See Ostacher, et al., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8553693/
4 Survey data collected Oct. 25-26, 2021, via online poll service. Participants were Veterans of the U.S. military diagnosed with PTSD.
5 See Virpi, et al., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3520420/